Macular Development in Aggressive Posterior Retinopathy of Prematurity
- PMID: 26167498
- PMCID: PMC4488519
- DOI: 10.1155/2015/808639
Macular Development in Aggressive Posterior Retinopathy of Prematurity
Abstract
Purpose. To report anatomic outcomes after early and confluent laser photocoagulation of the entire avascular retina, including areas in close proximity to the fovea, in patients with APROP. We aspire to demonstrate fundoscopic evidence of transverse growth and macular development following laser treatment in APROP. Methods. Retrospective review of 6 eyes with APROP that underwent confluent laser photocoagulation of the entire avascular retina. Photographic fundoscopic imaging was performed using the RetCam to compare outcomes after treatment. Results. Mean birth weight and gestational age were 704.8 g and 24.33 weeks, respectively. There were 2 females and 1 male. The average time to laser was 9.3 weeks after birth, with the mean postmenstrual age of 34 weeks. Two eyes had zone 1 and 4 eyes had posterior zone 2 disease. Three eyes developed 4A detachments, which were successfully treated. All 6 eyes experienced transverse growth, with expansion of the posterior pole and anterior displacement of the laser treatment. Conclusion. Confluent photocoagulation of the entire avascular retina, regardless of foveal proximity, should be the mainstay for treating APROP. Examination should be conducted within 5-10 days to examine areas previously hidden by neovascularization to ensure prudent therapy. Macular development involves both transverse and anterior-posterior growth.
Similar articles
-
Aggressive posterior retinopathy of prematurity: a review on current understanding.Eye (Lond). 2021 Apr;35(4):1140-1158. doi: 10.1038/s41433-021-01392-6. Epub 2021 Jan 29. Eye (Lond). 2021. PMID: 33514899 Free PMC article. Review.
-
Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.Retina. 2014 Jan;34(1):77-82. doi: 10.1097/IAE.0b013e318296e26d. Retina. 2014. PMID: 23807184
-
Diode laser photocoagulation posterior to the ridge in severe stage 3+ threshold retinopathy of prematurity.Cutan Ocul Toxicol. 2014 Sep;33(3):197-200. doi: 10.3109/15569527.2013.832687. Epub 2013 Oct 22. Cutan Ocul Toxicol. 2014. PMID: 24147941
-
Regression Rates Following the Treatment of Aggressive Posterior Retinopathy of Prematurity with Bevacizumab Versus Laser: 8-Year Retrospective Analysis.Med Sci Monit. 2016 Apr 10;22:1192-209. doi: 10.12659/msm.897095. Med Sci Monit. 2016. PMID: 27062023 Free PMC article.
-
Time to consider a new treatment protocol for aggressive posterior retinopathy of prematurity?Acta Ophthalmol. 2013 Mar;91(2):170-5. doi: 10.1111/j.1755-3768.2011.02351.x. Epub 2012 Jan 23. Acta Ophthalmol. 2013. PMID: 22268644
Cited by
-
Aggressive posterior retinopathy of prematurity: a review on current understanding.Eye (Lond). 2021 Apr;35(4):1140-1158. doi: 10.1038/s41433-021-01392-6. Epub 2021 Jan 29. Eye (Lond). 2021. PMID: 33514899 Free PMC article. Review.
-
Foveal Identification and Development in Prematurity-Implications on Zone Localization and Nutritional Supplementation.Invest Ophthalmol Vis Sci. 2025 Aug 1;66(11):17. doi: 10.1167/iovs.66.11.17. Invest Ophthalmol Vis Sci. 2025. PMID: 40772664 Free PMC article.
-
Aggressive Posterior Retinopathy of Prematurity (APROP): LASER as the Primary Modality of Treatment.J Ophthalmic Vis Res. 2021 Jul 29;16(3):400-407. doi: 10.18502/jovr.v16i3.9437. eCollection 2021 Jul-Sep. J Ophthalmic Vis Res. 2021. PMID: 34394869 Free PMC article.
-
Bevacizumab or laser for aggressive posterior retinopathy of prematurity.Taiwan J Ophthalmol. 2018 Oct-Dec;8(4):243-248. doi: 10.4103/tjo.tjo_69_18. Taiwan J Ophthalmol. 2018. PMID: 30637196 Free PMC article.
-
The role of substance P/neurokinin 1 receptor in the pathogenesis of esophageal squamous cell carcinoma through constitutively active PI3K/Akt/NF-κB signal transduction pathways.Mol Biol Rep. 2020 Mar;47(3):2253-2263. doi: 10.1007/s11033-020-05330-9. Epub 2020 Feb 18. Mol Biol Rep. 2020. Retraction in: Mol Biol Rep. 2024 May 25;51(1):696. doi: 10.1007/s11033-024-09649-5. PMID: 32072401 Retracted.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources